CURE has an FDA-registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform which includes CUREfilm®, one of the most advanced oral thin films on the market today; CUREpods™ a novel chewable delivery system and other more traditional dose forms that use advanced encapsulation technology. CUREform’s combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURE also holds the NSF® cGMP certification for manufacturing dietary supplements.
CURE’s clinical pipeline includes CUREfilm® Blue (sildenafil to treat erectile dysfunction), and CUREfilm® Canna (THC and CBD) each designed to optimize the pharmacokinetic profile of the medicine.
CURE partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S.A, Canada, Israel, and other markets.
Cure Pharmaceutical Corporation was founded in July 2011 and is a wholly-owned subsidiary of Cure Pharmaceutical Holding Corp, a public company.
1620 Beacon Place
Oxnard, CA 93033
We are positioned to advance numerous therapeutic categories, including pharmaceutical cannabis.
Our Investor Presentation
CURE Pharmaceutical Investor
Video Webcast | Dec. 17 2020
CBD, Cannabis and the Cannabiz
In the news
Seratopical Revolution Skincare Line by The Sera Labs Inc., a CURE Pharmaceutical Company, will be Available for Purchase this Fall at CVS, one of the Leading National Drug Store Chains
LOS ANGELES - Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced that all six facial products of the Seratopical Revolution skincare line will be available for purchase at CVS in the Fall of 2021. CVS is one of the leading...
CURE Pharmaceutical to Present at H.C. Wainwright 2021 Psychedelics in Psychiatry and Beyond Virtual Conference
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness markets, announced today that its Chief Business Officer Jonathan...
CURE Pharmaceutical Signs Agreement to Develop CBD and THC Oral Thin Films and Conduct Clinical Studies Targeting Veteran Health
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company, (BRC), an active Drug Enforcement...
Nicole Kidman and Sera Labs Inc., a CURE Pharmaceutical Company, Launch Seratopical Revolution and New Ad Campaign
The plant based, alcohol-free, non-CBD, anti-aging beauty line is available Wednesday, June 9 LOS ANGELES - Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), announced today a new ad campaign and launch of Seratopical Revolution, a new clean,...
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, today announced that it will hold a webcast with the investment community on Thursday, May 27, at 5 p.m. Eastern Daylight Time. Rob...
CURE Pharmaceutical First Quarter Revenue Quadruples to $1.5 million; Company Expands Clinical Pipeline to Include Psychedelics
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial results and provided an operational update for the first quarter ended March 31, 2021. First Quarter 2021 and...
Board of Directors
Chairman of the Board
Chief Executive Officer, Director
Chief Strategic Officer and Director, CEO of Wholly owned subsidiary, The Sera Labs.
(805) 410-9962 ext. 4
Continental Stock Transfer & Trust
1 State Street 30th Floor
New York, NY 10004-1561
805 3rd Avenue #1430
New York, NY 10022
10100 Santa Monica Blvd., 8th Fl.
Los Angeles, CA 90067